Los Angeles Capital Management
FDMT icon

Los Angeles Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Los Angeles Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.58K Sell
570
-27,019
-98% -$263K ﹤0.01% 2025
2026
Q1 		$257K Buy
27,589
+16,309
+145% +$142K ﹤0.01% 1076
2025
Q4 		$128K Hold
11,280
– – ﹤0.01% 1358
2025
Q3 		$98K Hold
11,280
– – ﹤0.01% 1321
2025
Q2 		$41.8K Buy
+11,280
New +$39.7K ﹤0.01% 1317

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Los Angeles Capital Management's FDMT Position: Q2 2026 in Review

Los Angeles Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 98% in Q2 2026, selling an estimated $263K and leaving 570 shares worth $7.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Los Angeles Capital Management first reported a position in FDMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $257K in Q1 2026. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Los Angeles Capital Management held 570 shares of 4D Molecular Therapeutics worth $7.58K as of Q2 2026.
  • Los Angeles Capital Management sold 27,019 4D Molecular Therapeutics shares in Q2 2026, an estimated $263K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2025 holding.
  • Los Angeles Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Los Angeles Capital Management's 4D Molecular Therapeutics position peaked at $257K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.